Brind.

Klotho Neurosciences received Orphan Drug Designation from the FDA for its KLTO-202 gene therapy, targeting ALS, Alzheimer's, and Parkinson's.

4 reports, 1 independent Updated Aug 18
Gone quiet
Reports
4
Developments
4
Repetition
25%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Klotho Neurosciences received Orphan Drug Designation from the FDA for its KLTO-202 gene therapy, targeting ALS, Alzheimer's, and Parkinson's.

Who's involved

What this event is mainly about
Als

How it developed

Newest first. Tap a step to see who reported it.
  1. Klotho Neurosciences will use AAVnerGene's platform for manufacturing its gene therapy.Sub-event
  2. FDA granted Orphan Drug Designation for KLTO-202, a gene therapy targeting ALS, AD, and PD.1 source
  3. Klotho Neurosciences is expanding its focus to identify key longevity indicators alongside its neurodegenerative disease targets.1 source
  4. Klotho Neurosciences regained Nasdaq compliance and continues developing therapies for ALS, Alzheimer's, and Parkinson's.1 source

Keep exploring

The entities involved

  • Als

    river in Vienna

    Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped
  • PR NewswireKlotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market Key partnerships, regulatory progress, manufactur
  • PR NewswireUPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology Company to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicat
  • PR NewswireKlotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK, July 24, 20
  • PR NewswireKlotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules Klotho Neurosciences Maintains Listing on the NASDAQ NEW YORK, July 16, 2025 /PRN